Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have received an average rating of “Hold” from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $12.50.
A number of research analysts have weighed in on ADAP shares. Leerink Swann reiterated an “outperform” rating and set a $15.00 target price on shares of Adaptimmune Therapeutics in a report on Friday, September 8th. BidaskClub raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $10.00 price target on shares of Adaptimmune Therapeutics in a research report on Thursday, October 12th. Zacks Investment Research raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a research report on Wednesday, October 4th. Finally, TheStreet raised Adaptimmune Therapeutics from a “d” rating to a “c” rating in a research report on Thursday, November 2nd.
Institutional investors and hedge funds have recently modified their holdings of the company. Alps Advisors Inc. boosted its position in shares of Adaptimmune Therapeutics by 4.9% in the 2nd quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 2,996 shares in the last quarter. Matrix Capital Management Company LP bought a new stake in shares of Adaptimmune Therapeutics in the 2nd quarter worth approximately $39,027,000. Baillie Gifford & Co. boosted its position in shares of Adaptimmune Therapeutics by 4.2% in the 3rd quarter. Baillie Gifford & Co. now owns 1,379,304 shares of the biotechnology company’s stock worth $11,297,000 after purchasing an additional 55,996 shares in the last quarter. Rathbone Brothers plc boosted its position in shares of Adaptimmune Therapeutics by 60.1% in the 3rd quarter. Rathbone Brothers plc now owns 321,050 shares of the biotechnology company’s stock worth $2,629,000 after purchasing an additional 120,525 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Adaptimmune Therapeutics by 75.4% in the 1st quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock worth $4,302,000 after purchasing an additional 335,700 shares in the last quarter. 67.93% of the stock is currently owned by hedge funds and other institutional investors.
Adaptimmune Therapeutics (ADAP) traded up $0.13 during mid-day trading on Friday, hitting $8.24. The company’s stock had a trading volume of 169,519 shares, compared to its average volume of 216,450. Adaptimmune Therapeutics has a 1 year low of $3.76 and a 1 year high of $9.29.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/05/adaptimmune-therapeutics-plc-adap-receives-consensus-recommendation-of-hold-from-analysts.html.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.